TUMOR MARKERS USED IN MONITORING THE TUMOR RECURRENCE IN PATIENTS WITH COLORECTAL CANCER

Authors

  • Claudia Burz
  • Ben Youssef Mohamed Aziz
  • Loredana Bălăcescu
  • Luminiţa Leluţiu
  • Rareş Buiga
  • Gabriel Samasca
  • Alexandru Irimie
  • Cosmin Lisencu

DOI:

https://doi.org/10.15386/cjmed-635

Keywords:

colon cancer, chemotherapy, predictive markers

Abstract

Background and aims. The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer.

Methods. A total of 30 patients diagnosed with colon cancer stage II or III who underwent optimal surgery were enrolled in study. Tumor markers CEA and CA 19-9 were determined before surgery. Tumor samples were prepared using tissue microarray kit (TMA) then stained for different cellular markers (Ki 67, HER2, BCL2, CD56, CD4, CD8) and analyzed using Inforatio programme for quantitative determination. All patients received standard adjuvant treatment, which consisted of eight cycles chemotherapy type XELOX. The patients were followed up for 3 years.

Results. Upon 3 years follow-up, 67% of patients developed tumor relapse, the most common site of metastasis being the liver. No correlations were observed between either serum or tissue tumor markers and the risk of tumor relapse.

Conclusion. Over 50% of patients with colon cancer who had optimal treatment developed metastasis. No statistically significant predictive value for investigated molecules was found. Future studies are needed to confirm the use of molecular markers in monitoring patients with colorectal cancer

Author Biographies

Claudia Burz, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca Department of Immunology, University of Medicine and Pharmacy Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca, Romania

Department of Immunology

Ben Youssef Mohamed Aziz, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Loredana Bălăcescu, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Luminiţa Leluţiu, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Rareş Buiga, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Gabriel Samasca, IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY, CLUJ-NAPOCA

IMMUNOLOGY

Alexandru Irimie, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca Department of Surgical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Department of Surgical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Cosmin Lisencu, Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca Department of Surgical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Prof. Dr. Ion Chiricuţă Cancer Institute, Cluj-Napoca

Department of Surgical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Downloads

Additional Files

Published

2016-07-31

How to Cite

1.
Burz C, Aziz BYM, Bălăcescu L, Leluţiu L, Buiga R, Samasca G, Irimie A, Lisencu C. TUMOR MARKERS USED IN MONITORING THE TUMOR RECURRENCE IN PATIENTS WITH COLORECTAL CANCER. Med Pharm Rep [Internet]. 2016 Jul. 31 [cited 2025 Oct. 5];89(3):378-83. Available from: https://medpharmareports.com/index.php/mpr/article/view/635

Issue

Section

Original Research